Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma

Next Previous
Trial Profile

Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Jan 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Oct 2007 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top